CNS Pharmaceuticals Statistics
Total Valuation
CNSP has a market cap or net worth of $3.21 million. The enterprise value is -$3.07 million.
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025, after market close.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CNSP has 2.94 million shares outstanding.
| Current Share Class | 2.94M |
| Shares Outstanding | 2.94M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +142.12% |
| Owned by Insiders (%) | 0.37% |
| Owned by Institutions (%) | 3.75% |
| Float | 2.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.24 |
| P/TBV Ratio | 0.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.43, with a Debt / Equity ratio of 0.05.
| Current Ratio | 3.43 |
| Quick Ratio | 2.91 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -924.44 |
Financial Efficiency
Return on equity (ROE) is -1,703.39% and return on invested capital (ROIC) is -785.51%.
| Return on Equity (ROE) | -1,703.39% |
| Return on Assets (ROA) | -179.08% |
| Return on Invested Capital (ROIC) | -785.51% |
| Return on Capital Employed (ROCE) | -241.26% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.97M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.80% in the last 52 weeks. The beta is 1.08, so CNSP's price volatility has been similar to the market average.
| Beta (5Y) | 1.08 |
| 52-Week Price Change | -99.80% |
| 50-Day Moving Average | 2.33 |
| 200-Day Moving Average | 8.98 |
| Relative Strength Index (RSI) | 38.32 |
| Average Volume (20 Days) | 213,232 |
Short Selling Information
The latest short interest is 338,694, so 11.50% of the outstanding shares have been sold short.
| Short Interest | 338,694 |
| Short Previous Month | 180,064 |
| Short % of Shares Out | 11.50% |
| Short % of Float | 11.59% |
| Short Ratio (days to cover) | 1.07 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -14.90M |
| Pretax Income | -17.46M |
| Net Income | -14.86M |
| EBITDA | -14.90M |
| EBIT | -14.90M |
| Earnings Per Share (EPS) | -$38.87 |
Full Income StatementBalance Sheet
The company has $6.46 million in cash and $326,072 in debt, giving a net cash position of $6.14 million or $2.08 per share.
| Cash & Cash Equivalents | 6.46M |
| Total Debt | 326,072 |
| Net Cash | 6.14M |
| Net Cash Per Share | $2.08 |
| Equity (Book Value) | 6.18M |
| Book Value Per Share | 4.37 |
| Working Capital | 6.13M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.11 million and capital expenditures -$4,188, giving a free cash flow of -$17.12 million.
| Operating Cash Flow | -17.11M |
| Capital Expenditures | -4,188 |
| Free Cash Flow | -17.12M |
| FCF Per Share | -$5.81 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |